Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 14/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5006682 | 0.90 | MAPT (0.52) | AVPR1AMAPTTP53KDM4EALDH1A1 | |
| SCHEMBL5219433 | 0.85 | AVPR1A (0.49) | AVPR1A | |
| SCHEMBL5215034 | 0.85 | MAPT (0.64) | AVPR1AMAPTTP53KDM4EALDH1A1 | |
| SCHEMBL5216250 | 0.84 | AVPR1A (0.48) | AVPR1AKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5006747 | 0.84 | AVPR1A (0.57) | AVPR1AMAPTTP53 | |
| SCHEMBL5008978 | 0.82 | AVPR1A (0.53) | AVPR1A | |
| SCHEMBL5215082 | 0.82 | AVPR1A (0.50) | AVPR1AMAPT | |
| SCHEMBL5216029 | 0.81 | AVPR1A (0.47) | AVPR1AMAPTTP53KDM4EALDH1A1 | |
| SCHEMBL5211585 | 0.81 | AVPR1A (0.47) | AVPR1AMAPTTP53 | |
| SCHEMBL5108048 | 0.80 | AVPR1A (0.50) | AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449462-B2 | Triazole derivatives which inhibit vasopressin antagonistic activity | PFIZER, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449462-B2 | Triazole derivatives which inhibit vasopressin antagonistic activity | PFIZER, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449462-B2 | Triazole derivatives which inhibit vasopressin antagonistic activity | PFIZER, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070203132-A1 | Triazole derivatives which inhibit vasopressin antagonistic activity | PFIZER INC | 2007-08-30 | — | — | US | disclosed |
| US-20070203132-A1 | Triazole derivatives which inhibit vasopressin antagonistic activity | PFIZER INC | 2007-08-30 | — | — | US | disclosed |
| US-20070203132-A1 | Triazole derivatives which inhibit vasopressin antagonistic activity | PFIZER INC | 2007-08-30 | — | — | US | disclosed |
| EP-1708718-A1 | TRIAZOLE DERIVATIVES WHICH INHIBIT VASOPRESSIN ANTAGONISTIC ACTIVITY | Pfizer Limited (GB) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005079808-A1 | TRIAZOLE DERIVATIVES WHICH INHIBIT VASOPRESSIN ANTAGONISTIC ACTIVITY | PFIZER LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005079808-A1 | TRIAZOLE DERIVATIVES WHICH INHIBIT VASOPRESSIN ANTAGONISTIC ACTIVITY | PFIZER LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203132-A1 | Triazole derivatives which inhibit vasopressin antagonistic activity | AVPR2, PRLHR, AVPR1A | AVPR1A 3/4885MAPT 4597/4885TP53 4301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.